Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ICAD

Market Cap 106M 91.63M 84.47M 79.15M 148M 10.11B 151M 1.01B 390M 4.87B 396M 388M 16.95B P/E Ratio 2023
-9.35x
P/E Ratio 2024 -8.59x
Enterprise Value 88.75M 77.02M 70.99M 66.52M 124M 8.5B 127M 847M 328M 4.1B 333M 326M 14.24B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 year 3.58
Extreme 3.58
3.99
3 years 1.14
Extreme 1.14
4.02
5 years 1.05
Extreme 1.05
19
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Date Insider Type Main position Quantity % Market Cap.
17/07/25Issuer sale

Director

87,408 0.3293%
17/07/25Issuer sale

Chief Financial Officer

158,488 0.5972%
17/07/25Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%+0.52%+222.50% 106M
-1.32%-1.32%+14.58%-8.21% 177B
+0.21%-1.41%-20.96%+32.02% 146B
-1.55%-3.13%-11.69%-23.19% 128B
-2.42%-3.44%-52.55%-8.01% 70.11B
-0.26%-1.93%+13.63%+1.97% 49.38B
+0.93%-0.66%-25.43%-34.35% 44.23B
-1.57%-6.37%+8.21%+11.88% 36.59B
-0.95%-4.44%+3.96%+44.31% 35.32B
+1.18%+1.10%-12.11%-16.33% 29.35B
Average +0.01%-1.95%-8.18%+22.26% 71.6B
Weighted average by Cap. -0.53%-2.08%-8.43%-0.24%

Financials

2023 2024
Net sales 17.32M 15.03M 13.85M 12.98M 24.25M 1.66B 24.76M 165M 63.98M 799M 65.01M 63.61M 2.78B 19.61M 17.02M 15.68M 14.7M 27.46M 1.88B 28.03M 187M 72.44M 905M 73.61M 72.02M 3.15B
Net income -4.85M -4.21M -3.88M -3.63M -6.79M -464M -6.93M -46.25M -17.91M -224M -18.2M -17.8M -778M -5.62M -4.87M -4.49M -4.21M -7.86M -538M -8.03M -53.59M -20.75M -259M -21.08M -20.63M -901M
Net Debt -21.21M -18.41M -16.97M -15.9M -29.7M -2.03B -30.32M -202M -78.35M -979M -79.62M -77.9M -3.4B -16.84M -14.62M -13.47M -12.63M -23.59M -1.61B -24.08M -161M -62.23M -777M -63.23M -61.87M -2.7B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!